These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 28219449)

  • 1. Ex vivo
    Portelius E; Mattsson N; Pannee J; Zetterberg H; Gisslén M; Vanderstichele H; Gkanatsiou E; Crespi GA; Parker MW; Miles LA; Gobom J; Blennow K
    Mol Neurodegener; 2017 Feb; 12(1):18. PubMed ID: 28219449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isobaric Quantification of Cerebrospinal Fluid Amyloid-β Peptides in Alzheimer's Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration.
    Rogeberg M; Almdahl IS; Wettergreen M; Nilsson LN; Fladby T
    J Proteome Res; 2015 Nov; 14(11):4834-43. PubMed ID: 26452689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of amyloid beta mid-domain fragments in human cerebrospinal fluid.
    Rogeberg M; Wettergreen M; Nilsson LN; Fladby T
    Biochimie; 2015 Jun; 113():86-92. PubMed ID: 25866191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.
    Augutis K; Axelsson M; Portelius E; Brinkmalm G; Andreasson U; Gustavsson MK; Malmeström C; Lycke J; Blennow K; Zetterberg H; Mattsson N
    Mult Scler; 2013 Apr; 19(5):543-52. PubMed ID: 23069872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Small Peptides in Human Cerebrospinal Fluid upon Amyloid-β Degradation.
    Mizuta N; Yanagida K; Kodama T; Tomonaga T; Takami M; Oyama H; Kudo T; Ikeda M; Takeda M; Tagami S; Okochi M
    Neurodegener Dis; 2017; 17(2-3):103-109. PubMed ID: 28103595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - inverse correlation with dementia severity.
    Hock C; Golombowski S; Müller-Spahn F; Naser W; Beyreuther K; Mönning U; Schenk D; Vigo-Pelfrey C; Bush AM; Moir R; Tanzi RE; Growdon JH; Nitsch RM
    Eur Neurol; 1998; 39(2):111-8. PubMed ID: 9520072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays.
    Schauer SP; Mylott WR; Yuan M; Jenkins RG; Rodney Mathews W; Honigberg LA; Wildsmith KR
    Alzheimers Res Ther; 2018 Nov; 10(1):118. PubMed ID: 30486870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protofibrillar and Fibrillar Amyloid-β Binding Proteins in Cerebrospinal Fluid.
    Rahman MM; Westermark GT; Zetterberg H; Härd T; Sandgren M
    J Alzheimers Dis; 2018; 66(3):1053-1064. PubMed ID: 30372682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel APP/Abeta isoforms in human cerebrospinal fluid.
    Portelius E; Brinkmalm G; Tran AJ; Zetterberg H; Westman-Brinkmalm A; Blennow K
    Neurodegener Dis; 2009; 6(3):87-94. PubMed ID: 19229112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry.
    Oe T; Ackermann BL; Inoue K; Berna MJ; Garner CO; Gelfanova V; Dean RA; Siemers ER; Holtzman DM; Farlow MR; Blair IA
    Rapid Commun Mass Spectrom; 2006; 20(24):3723-35. PubMed ID: 17117458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered cerebrospinal fluid levels of amyloid β and amyloid precursor-like protein 1 peptides in Down's syndrome.
    Portelius E; Hölttä M; Soininen H; Bjerke M; Zetterberg H; Westerlund A; Herukka SK; Blennow K; Mattsson N
    Neuromolecular Med; 2014 Jun; 16(2):510-6. PubMed ID: 24740518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of β-amyloid species in canine cerebrospinal fluid by mass spectrometry.
    Sarasa L; Allué JA; Pesini P; González-Martínez A; Sarasa M
    Neurobiol Aging; 2013 Sep; 34(9):2125-32. PubMed ID: 23582658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Young to Middle-Aged Dogs with High Amyloid-β Levels in Cerebrospinal Fluid are Impaired on Learning in Standard Cognition tests.
    Borghys H; Van Broeck B; Dhuyvetter D; Jacobs T; de Waepenaert K; Erkens T; Brooks M; Thevarkunnel S; Araujo JA
    J Alzheimers Dis; 2017; 56(2):763-774. PubMed ID: 28035921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid-beta isoform metabolism quantitation by stable isotope-labeled kinetics.
    Mawuenyega KG; Kasten T; Sigurdson W; Bateman RJ
    Anal Biochem; 2013 Sep; 440(1):56-62. PubMed ID: 23714261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid.
    Gabelle A; Roche S; Gény C; Bennys K; Labauge P; Tholance Y; Quadrio I; Tiers L; Gor B; Chaulet C; Vighetto A; Croisile B; Krolak-Salmon P; Touchon J; Perret-Liaudet A; Lehmann S
    Brain Res; 2010 Oct; 1357():175-83. PubMed ID: 20713025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain.
    Hey JA; Kocis P; Hort J; Abushakra S; Power A; Vyhnálek M; Yu JY; Tolar M
    CNS Drugs; 2018 Sep; 32(9):849-861. PubMed ID: 30076539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease.
    Brinkmalm G; Brinkmalm A; Bourgeois P; Persson R; Hansson O; Portelius E; Mercken M; Andreasson U; Parent S; Lipari F; Ohrfelt A; Bjerke M; Minthon L; Zetterberg H; Blennow K; Nutu M
    Brain Res; 2013 Jun; 1513():117-26. PubMed ID: 23541617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.
    Farlow M; Arnold SE; van Dyck CH; Aisen PS; Snider BJ; Porsteinsson AP; Friedrich S; Dean RA; Gonzales C; Sethuraman G; DeMattos RB; Mohs R; Paul SM; Siemers ER
    Alzheimers Dement; 2012 Jul; 8(4):261-71. PubMed ID: 22672770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab.
    Lachno DR; Evert BA; Vanderstichele H; Robertson M; Demattos RB; Konrad RJ; Talbot JA; Racke MM; Dean RA
    J Alzheimers Dis; 2013; 34(4):897-910. PubMed ID: 23302661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.